Paradigm Biopharmaceuticals Limited

ASX:PAR.AX

0.22 (AUD) • At close November 5, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) AUD.

2024 Q42024 Q22023 Q42023 Q22022 Q42022 Q22021 Q42021 Q22020 Q42020 Q22019 Q42019 Q22018 Q42018 Q22017 Q42017 Q22016 Q42016 Q22015 Q42015 Q32015 Q2
Revenue 0.06600.0420.0050.0340.0450.0210-0.8260.8262.9560.0282.660.0221.7660.0581.2440.046000
Cost of Revenue 0.0090.0730.0880.0840.1690.1680.2060.1030000000000000
Gross Profit 0.057-0.073-0.046-0.08-0.135-0.122-0.185-0.103-0.8260.8262.9560.0282.660.0221.7660.0581.2440.046000
Gross Profit Ratio 0.8630-1.098-16.89-3.981-2.706-9.02501111111111000
Reseach & Development Expenses 11.95946.37424.94927.7315.56223.4516.32217.1958.4784.3164.7083.1883.8862.7082.5171.7161.9360.9320.12900.029
General & Administrative Expenses 2.6973.5192.0014.5634.1543.7815.0973.6521.341.60.7250.7470.7610.5230.4640.8370.4450.3050.0500.17
Selling & Marketing Expenses 0.30.2530.360.4620.4990.420.7170.1191.22701.8690.4930.6250.3650.2680.3230.4430.2310.78400.411
SG&A 2.9973.4461.9244.4874.0573.6844.993.5482.5671.62.8071.241.3860.8870.7321.160.8880.5370.83400.581
Other Expenses 000000000000000000000
Operating Expenses 14.95749.8226.87432.21619.6227.13321.31220.74311.0445.9167.5164.4285.3313.5963.2482.8762.851.4690.96200.61
Operating Income -14.966-49.893-26.92-32.296-19.755-27.256-21.497-20.847-11.044-5.916-7.516-4.4-2.671-3.573-1.483-2.818-1.605-1.423-0.9620-0.61
Operating Income Ratio -227.4390-640.19-6,856.864-580.621-603.001-1,046.084013.372-7.162-2.543-156.371-1.004-159.984-0.84-48.918-1.29-30.861000
Total Other Income Expenses Net 5.271-0.1260.611-0.3477.4910.2717.930.1163.8490.812-3.71100.05400.02600.10400.00200.005
Income Before Tax -9.695-50.02-26.309-32.643-12.265-26.985-13.567-20.73-7.195-5.104-11.227-4.4-2.617-3.573-1.457-2.818-1.502-1.423-0.960-0.605
Income Before Tax Ratio -147.3370-625.657-6,930.641-360.468-597.014-660.1808.711-6.18-3.798-156.371-0.984-159.984-0.825-48.918-1.207-30.861000
Income Tax Expense -4.986-1.061-6.266-0.776-000-0-0.8260.8262.95600000000.00200.005
Net Income -9.695-48.958-20.043-31.867-12.265-26.985-13.567-20.73-7.195-5.104-11.227-4.4-2.617-3.573-1.457-2.818-1.502-1.423-0.960-0.605
Net Income Ratio -147.3370-476.637-6,765.908-360.468-597.014-660.1808.711-6.18-3.798-156.371-0.984-159.984-0.825-48.918-1.207-30.861000
EPS -0.034-0.16-0.069-0.12-0.051-0.11-0.057-0.088-0.034-0.026-0.075-0.034-0.025-0.03-0.014-0.031-0.018-0.019-0.0190-0.037
EPS Diluted -0.034-0.16-0.069-0.12-0.051-0.11-0.057-0.088-0.034-0.026-0.075-0.034-0.025-0.03-0.014-0.031-0.018-0.019-0.0190-0.037
EBITDA -14.892-49.82-26.843-32.219-19.659-27.159-21.39-20.743-11.865-5.017-4.554-4.398-2.664-3.565-1.467-2.817-1.603-1.4220.00200.005
EBITDA Ratio -226.3250-638.364-6,840.537-577.788-600.858-1,040.883014.365-6.074-1.541-156.298-1.001-159.612-0.831-48.896-1.288-30.85000